In 104 patients with relapsed-refractory multiple myeloma, adding cyclophosphamide to pomalidomide-dexamethasone did not significantly improve progression-free survival (median 6.9 vs 4.6 months); the phase 2 trial closed early and was underpowered. Response rate was higher.
RCTn = 104
Hall et al. Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial